Vadadustat
Vafseo (vadadustat) is a small molecule pharmaceutical. Vadadustat was first approved as Vafseo on 2023-04-24. It has been approved in Europe to treat anemia and chronic renal insufficiency. It is known to target egl nine homolog 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 8 | 6 | — | — | 14 |
| Chronic renal insufficiency | D051436 | N18 | 1 | 4 | 5 | — | — | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | — | — | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VADADUSTAT |
| INN | vadadustat |
| Description | Vadadustat, sold under the brand name Vafseo is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 1000025-07-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3646221 |
| ChEBI ID | — |
| PubChem CID | 23634441 |
| DrugBank | DB12255 |
| UNII ID | I60W9520VV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EGLN1
EGLN1
Organism
Homo sapiens
Gene name
EGLN1
Gene synonyms
C1orf12
NCBI Gene ID
Protein name
egl nine homolog 1
Protein synonyms
egl nine-like protein 1, HIF-PH2, HIF-prolyl hydroxylase 2, HPH-2, Hypoxia-inducible factor prolyl hydroxylase 2, PHD2, Prolyl hydroxylase domain-containing protein 2, SM-20, zinc finger MYND domain-containing protein 6
Uniprot ID
Mouse ortholog
Egln1 (112405)
egl nine homolog 1 (Q922P3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 253 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more